13价肺炎球菌结合疫苗在重症慢性肾病患者中的免疫原性与安全性
研究纳入74例未接种和58例既往接种过PPV23(>1年前)的重症(4-5期)慢性肾病患者,评估PCV13免疫原性与安全性。结果显示既往PPV23接种者PCV13抗体应答劣于未接种者,两组对血清型3应答最低;既往接种者全身不良事件更常见但均为轻中度。
要点
- 重症CKD患者中,既往PPV23接种超过1年者PCV13抗体应答劣于未接种者。
- 两组对血清型3的PCV13应答均最低。
- 既往PPV23接种者PCV13后全身不良事件更常见,但未超出轻中度范围。
核心结论
- 在重症(4-5期)CKD患者中,既往PPV23接种超过1年者接种PCV13的抗体应答劣于未接种肺炎球菌疫苗者。
- 两组对血清型3的PCV13应答均最低。
- 既往PPV23接种可能与PCV13后全身不良事件更常见相关,但均为轻中度。
研究设计与样本
- 研究纳入74例未接种PPV23和58例既往接种PPV23(>1年前)的重症(4-5期)CKD患者。
- 检测7种血清型(3、6B、9V、14、19A、19F、23F)特异性IgG、IgM和IgA在免疫前、免疫后4周和1年的浓度。
主要发现
- 既往PPV23接种者多数血清型特异性IgG和IgM及血清型3特异性IgA基线浓度高于未接种者。
- PCV13显著提高几乎所有血清型特异性IgG、全部IgA和部分IgM,部分血清型特异性IgG和IgM升高持续1年。
- 多数血清型特异性IgG和部分IgA的抗体浓度倍数增长及>2倍增长个体比例,未接种者一般大于既往接种者。
- 两组对PCV13应答最低的均为血清型3。
- 原住民背景患者对PCV13免疫应答优于非原住民,部分可能与原住民参与者年龄较轻有关。
临床怎么用
- 对重症CKD患者评估肺炎球菌疫苗接种史,既往PPV23接种可能影响后续PCV13的抗体应答。
- PCV13在重症CKD患者中总体安全,既往PPV23接种者需关注全身不良事件但多为轻中度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals with chronic kidney disease (CKD) are at high risk of pneumococcal infections and recommended to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23). Although the 13-valent pneumococcal conjugate vaccine (PCV13) has been found to have higher immunogenicity compared to PPV23 in adults with some immunocompromising conditions, previous PPV23 immunization may decrease the immunogenicity of PCV13. We assessed immunogenicity and safety of PCV13 in 74 PPV23-naïve and 58 previously PPV23-immunized (>1 year ago) patients with severe (stage 4-5) CKD. Serum IgG, IgM, and IgA specific to seven serotypes, i.e. 3, 6B, 9V, 14, 19A, 19F, 23F were quantified pre- and 4 weeks and one year post-immunization. Baseline concentrations for most serotype-specific IgG and IgM, and serotype 3-specific IgA were higher in previously PPV23-immunized compared to PPV23-naïve patients. Immunization with PCV13 significantly increased almost all serotype-specific IgG, all IgA and some IgM; an increase in some serotype-specific IgG and IgM lasted for one year. Fold increases in antibody concentrations and the proportion of individuals with >2-fold increase post-immunization were generally larger in PPV23-naïve than previously immunized patients for most serotype-specific IgG and some IgA. The data show that in patients with CKD who received previous PPV23 immunization over one year ago, the antibody response to PCV13 was inferior compared to pneumococcal vaccine naïve study participants. In both groups, the lowest response to PCV13 was found for serotype 3. Patients of Indigenous ethnic background demonstrated a superior immune response to PCV13 compared to the non-Indigenous counterpart that could partially be related to Indigenous study participants' younger age. Although we found that previous PPV23 immunization could contribute to the more frequent occurrence of systemic adverse events post PCV13 immunization, those did not exceed the mild to moderate range.
引用
- Ulanova M, Huska B, Desbiens A, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease. Vaccine. 2020. PMID: 33358702. doi:10.1016/j.vaccine.2020.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。